{
    "organizations": [],
    "uuid": "96bbbb0f3e4d9065ac91124d528b5cb75d1dae09",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tonix-pharma-ready-to-file-for-app/brief-tonix-pharma-ready-to-file-for-approval-of-ptsd-treatment-in-2019-based-on-study-data-idUSASC09UMW",
    "ord_in_thread": 0,
    "title": "BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Tonix Pharmaceuticals Holding Corp :\n* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD\n* TONIX PHARMACEUTICALS HOLDING CORP - ‍TOPLINE RESULTS OF ABOUT 550 PARTICIPANTS WITH MILITARY-RELATED PTSD EXPECTED IN Q4 2018​\n* TONIX PHARMACEUTICALS HOLDING - ‍PHASE 3 HONOR STUDY ENROLLMENT CONTINUES & INTERIM RESULTS OF FIRST 50 PERCENT OF PARTICIPANTS EXPECTED IN Q3 2018​\n* TONIX PHARMACEUTICALS - EVIDENCE FROM PHASE 2 STUDY OF TONMYA SHOWED POTENTIAL IMPROVEMENT OVER EXISTING THERAPIES USED TO TREAT MILITARY-RELATED PTSD​\n* TONIX PHARMACEUTICALS HOLDING CORP - CO IS READY TO FILE NDA FOR TONMYA FOR TREATMENT OF PTSD IN 2019 IN EVENT OF A PERSUASIVE OUTCOME OF HONOR STUDY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T19:36:00.000+03:00",
    "crawled": "2018-04-04T12:21:19.061+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "tonix",
        "pharmaceutical",
        "holding",
        "corp",
        "tonix",
        "pharmaceutical",
        "achieves",
        "percent",
        "enrollment",
        "phase",
        "trial",
        "breakthrough",
        "therapy",
        "cyclobenzaprine",
        "hcl",
        "sublingual",
        "tablet",
        "treatment",
        "ptsd",
        "tonix",
        "pharmaceutical",
        "holding",
        "corp",
        "result",
        "participant",
        "ptsd",
        "expected",
        "q4",
        "tonix",
        "pharmaceutical",
        "holding",
        "honor",
        "study",
        "enrollment",
        "continues",
        "interim",
        "result",
        "first",
        "percent",
        "participant",
        "expected",
        "q3",
        "tonix",
        "pharmaceutical",
        "evidence",
        "phase",
        "study",
        "tonmya",
        "showed",
        "potential",
        "improvement",
        "existing",
        "therapy",
        "used",
        "treat",
        "tonix",
        "pharmaceutical",
        "holding",
        "corp",
        "co",
        "ready",
        "file",
        "nda",
        "tonmya",
        "treatment",
        "ptsd",
        "event",
        "persuasive",
        "outcome",
        "honor",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}